Skip to main content
. 2022 Sep 9;101(36):e30170. doi: 10.1097/MD.0000000000030170

Table 3.

Treatment-related adverse reactions.

Side effect RCT NRCT Cohort study
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
Myelosuppression OR 1.26 (0.75–2.09) OR 1.15 (0.19–6.94)
Leukopenia OR 0.78 (0.24–2.49)
Neutropenia OR 0.36(0.15–0.85)*
Thrombocytopenia OR 1.08 (0.55–2.14) OR 0.71 (0.20–2.51)
Anemia OR 0.72 (0.28–1.81) OR 0.75 (0.23–2.44)
Bleeding OR 1.68 (0.63–4.49)
cardiovascular toxicity OR 6.60 (0.77–56.65)
Liver and kidney dysfunction OR 0.79 (0.21–3.03) OR 1.10 (0.58–2.09)
Neurotoxicity OR 1.75 (0.56–5.48)
Gastrointestinal reaction OR 0.80 (0.37–1.71) OR 1.24 (0.74–2.10) OR 2.15 (0.42–11.03)
Nausea OR 0.74 (0.32–1.68)
Vomiting OR 0.85 (0.34–2.10)
Diarrhea OR 0.81 (0.45–1.46) OR 4.53 (1.60–12.84)**
Radiation proctitis OR 1.67 (0.49–5.72) OR 0.95 (0.47–1.91) OR 0.25 (0.10–0.66)**
Radiation cystitis OR 2.29 (0.20–26.22) OR 1.00 (0.18–5.51)
Rash OR 1.49 (0.55–4.04)
Fever OR 1.67 (0.42–6.61)
Alopecia OR 1.46 (0.43–4.93) OR 0.78 (0.25–2.39) OR 2.89 (0.91–9.17)
Hypertension OR 10.80 (1.25–93.44)*
Genitourinary tract reaction OR 1.22 (0.14–11.01) OR 0.87 (0.30–2.48) OR 1.50 (0.27–8.28)

CI = confidence interval, NRCT = nonrandomized controlled trial, OR = odds ratio, RCT = randomized controlled trial.

*P < 0.05, **P < 0.01.